Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eman Elkadry

Urogynecology and Reconstructive Pelvic Surgery Cambridge, MA Medical Doctor

NPI 1033189089 CMS profile 319213

725 Concord Ave, Ste 3300, Cambridge, MA 02138

Open in the dashboard

General payments

$130,268

323 records reported · program years 2019–2025

Research payments

$5,263

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12,983 paid to institutions, not to them · program year 2019

Through program year 2025, Eman Elkadry of Cambridge, MA is reported in the CMS Open Payments database as having received $130,268 across 323 general payments and $5,263 in research payments paid to them. Separately, studies naming them as principal investigator received $12,983 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22,315 31
2025 Research $2,900 1
2024 General $23,598 49
2023 General $15,664 42
2023 Research $2,363 1
2022 General $27,796 78
2021 General $19,654 40
2020 General $9,376 33
2019 General $11,865 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eman Elkadry
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Eman Elkadry were reported at $22,315. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Eman Elkadry Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $11,865 $358 $132–$1,270 $163
2020 $9,376 $198 $86–$642 $114
2021 $19,654 $361 $118–$1,182 $132
2022 $27,796 $410 $128–$1,175 $149
2023 $15,664 $434 $152–$1,344 $160
2024 $23,598 $494 $193–$1,331 $164
2025 $22,315 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $85,645 142 payments
  2. Allergan Inc. $40,539 84 payments
  3. Boston Scientific Corporation $961 11 payments
  4. Coloplast Corp $887 10 payments
  5. Astellas Pharma US Inc $547 22 payments
  6. Caldera Medical, Inc $435 6 payments
  7. Pfizer Inc. $343 22 payments
  8. Axonics Modulation Technologies, Inc. $252 4 payments
  9. Medtronic, Inc. $220 5 payments
  10. Urovant Sciences Inc $95 5 payments
  11. Other $343 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $88,219 45 payments
  2. Consulting Fee $20,418 12 payments
  3. Travel and Lodging $12,461 49 payments
  4. Food and Beverage $8,558 207 payments
  5. Education $532 9 payments
  6. Gift $80 1 payment
Products named General payments · program years 2019–2025
  1. BOTOX Urology $89,926 124 payments
  2. BOTOX Urology $11,043 21 payments
  3. BOTOX Urology $8,874 13 payments
  4. BOTOX Neuroscience $1,181 1 payment
  5. BOTOX Botox Therapeutic $604 23 payments
  6. Altis Women's Health $516 5 payments
  7. BOTOX Hyperhydrosis $449 25 payments
  8. Desara $435 6 payments
  9. Axonics $403 4 payments
  10. ALTIS Female Incontinence $371 5 payments
  11. Other $2,964 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $5,263 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

502

Median for Obstetrics & Gynecology: 65

Drug cost

$108,900

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

45.4%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 58 $45,936
Myrbetriq Mirabegron Brand 46 $34,461
Estradiol Generic 172 $14,800
Premarin Estrogens, Conjugated Brand 21 $7,797
Yuvafem Estradiol Brand 22 $3,738
Trimethoprim Generic 15 $521
Methenamine Hippurate Generic 11 $510
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 58 $411
Lorazepam Generic 12 $255
Oxybutynin Chloride Er Oxybutynin Chloride Brand 11 $188

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$83,536

Of which drugs: $24,461

Medicare patients

198

Average age 74

Services billed

5,638

198 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 55%
Osteoporosis 33%
Depression 29%
Diabetes 20%
Ischemic heart disease 17%
Chronic kidney disease 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 12 4,900 $24,431

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $22,956
$22,956 — 4,900

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record